In addition, tLyP-1-conjugated nanoparticles selectively home to tumor tissue, penetrate the blood vessels, and enter the tumor parenchyma with greater potency than the parent peptide LyP-1 [35–38]. The gene discussed is PTPN22; the disease is neoplasm.